BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ (BIBCL) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ ₹34.24, price ₹8.18, upside +318.6%, quality 38 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 27, 2026.
How to read this chart
60‑month range ₹8.18 – ₹90.00 · fair‑value band ₹27.25 – ₹47.46 · the ₹8.18 price screens below the ₹34.24 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 27, 2026.
Follow BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ in your weekly email
Every Wednesday you see whether BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Bharat Immunologicals & Biologicals Corporation Limited, a biotechnology company, engages in the manufacture and sale of pharmaceutical products in India. It offers oral polio vaccines, zinc tablets, diarrhea management kits, and BIB sweet tablets. The company was incorporated in 1989 and is based in Bulandshahr, India.
Stock analysis
BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ (BIBCL) currently trades at ₹8.18, while our model-based Fair Value estimate is ₹34.24, implying the stock looks roughly 76.1% undervalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of ₹36.83 per share, and 7 of the 7 models we run sit above the ₹8.18 price.
Bear case: the Asset-Based group reads lowest at ₹13.69, and 0 of the 7 models stay below the price. Evidence for this calculation is low.
Scenario range: ₹27.25 (bear) to ₹47.46 (bull), the price of ₹8.18 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 38/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ reported revenue of ₹446M in FY2023 versus ₹836M in FY2019, a compound −14.5%/yr. Reported net income was −₹166M in FY2023.
Key figures
Market cap ₹572M (≈ $5.9M) · P/S ratio 7.48 · EPS (TTM) ₹−2.73 · Net margin −37.3% · Return on equity −21.0% · Return on assets (EBIT) −9.4% · Operating margin −2,888% · Free cash flow ₹109M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).
What moves the price
The share trades about 63% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at 319%, BIBCL screens cheaper than that median.
Fair Value models
Bear ₹27.25Fair Value ₹34.24Bull ₹47.46
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.15/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−43.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−12.6%
’19
’20
’21
’22
’23
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−11.5% (2019) → −35.9% (2023)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2023 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−1.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (India: IMF forecast 4.1% a year to 2030, 4.7% from 2016 to 2025) that is about −5.4% a year for the price.
Compare BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 614 stocks
Beats the industry median on 3/5 measures
Overall it ranks above its industry peers.
Valuation
Quality Score38 · Below median
Fair Value upside+200.0% · Top 25%
Profitability
Return on assets−6.3% · Above median
Net margin (TTM)−37.3% · Bottom 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ (BIBCL) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of ₹34.24 versus a price of ₹8.18, about +319% upside (undervalued).
What is the fair value of BIBCL?
Our model-based fair value for BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ is ₹34.24 (as of Sep 27, 2026), built from audited fundamentals. The current price: ₹8.18.
What is the quality score of BIBCL?
BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ has a Quality Score of 38/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ (BIBCL)?
Our model-based price target is the fair value of ₹34.24 (as of Sep 27, 2026) from 7 valuation models. Cautious scenario ₹27.25, optimistic scenario ₹47.46. It is a calculation from audited fundamentals, not an analyst target.
What is the BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ stock forecast for 2026?
Our models put fair value at ₹34.24, about +319% upside versus a price of ₹8.18 (undervalued). Cautious scenario ₹27.25, optimistic scenario ₹47.46. The calculation is refreshed regularly with new filings.
What growth is priced into BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ (BIBCL)?
For today's price to be fair in a discounted-cash-flow model, BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ would have to grow free cash flow by -1.5 % per year for five years (discount rate 10.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 4 years revenue grew -14.5 % per year. As of Sep 27, 2026.
What discount rate (WACC) does the fair value of BIBCL use?
Our models discount BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ at 10.9 %: a base by market capitalisation (nano), damped by beta 0.43, country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ that is -1.5 % per year a year over ten years, using the same discount rate (10.9 %) and the same formula as our fair value.
How much growth has BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ (BIBCL) delivered so far?
Over the past 4 years revenue at BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ grew -14.5 % a year. The price currently implies -1.5 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ (BIBCL) growing?
The median revenue growth in the sector is +1.7 % a year. That is the yardstick for the growth priced into BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ (-1.5 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ (BIBCL)?
The free-cash-flow yield on the price is 30.84 %: that much free cash flow BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ produces per unit of market value. When it exceeds the discount rate of our models (10.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ (BIBCL)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ it is ₹34.24 per share (as of Sep 27, 2026), against a price of ₹8.18. It is the blended result of 7 valuation models (cash flow, earnings, asset, dividend).
Is BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ stock overvalued or undervalued in 2026?
As of Sep 27, 2026, BIBCL trades below its calculated fair value: price ₹8.18, fair value ₹34.24, a gap of about +319% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BIBCL?
No. The price is what the market pays today (₹8.18); the fair value is what the company's own numbers justify (₹34.24). For BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ the two are ₹26.06 per share apart. That gap is exactly why we show both numbers side by side.
How much is BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ worth?
The market values BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ at about ₹572M (market capitalisation, as of Sep 27, 2026). Per share that is ₹8.18; our models calculate a fair value of ₹34.24 per share.
What do the bullish and bearish scenarios say about BIBCL?
Our models span a range for BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$: cautious scenario ₹27.25, base ₹34.24, optimistic ₹47.46 per share (as of Sep 27, 2026, price ₹8.18). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ (BIBCL)?
Balance-sheet figures for BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ (as of Sep 27, 2026): return on equity −21.0%. They feed the Quality Score of 38/100, which measures business quality independently of the share price.
How far is BIBCL from its 52-week high?
BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ trades at ₹8.18, about 63% below its 52-week high of ₹21.95 and at the low of ₹8.18 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹34.24 is for.
Which stocks are comparable to BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ stock attractive at the current price?
The data as of Sep 27, 2026: price ₹8.18, calculated fair value ₹34.24 (+319%), Quality Score 38/100, from 7 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BIBCL calculated?
We run BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ through 7 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹34.24, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ currently trades 76 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ (BIBCL)?
The closing price on Oct 1, 2026 was ₹8.18. Our model-based fair value is ₹34.24, about +319% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ right now?
The large discount to fair value meets weak quality (38/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (₹27.25). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$
How large is the market capitalisation of BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ (BIBCL)?
The market capitalisation of BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ is ₹572M (≈ $5.9M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ (BIBCL)?
The price-to-sales ratio of BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ is 7.48 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ (BIBCL)?
Earnings per share at BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ are ₹−2.73. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ (BIBCL)?
The net margin of BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ is −37.3% (fiscal year 2023). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ (BIBCL)?
The return on equity (ROE) of BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ is −21.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ (BIBCL)?
On an EBIT basis the return on assets of BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ is −9.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ (BIBCL)?
The operating margin of BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ is −2,888% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much net debt does BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ (BIBCL) carry?
The net debt of BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ is ₹689M (fiscal year 2023, ≈ 6.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ in the live analysis
One click puts BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LTD.-$ on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
